Here are the 10-Q quarterly reports from AtaiBeckley Inc. (ATAI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ATAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATAI filings page.
AtaiBeckley Inc., a clinical-stage mental health biotech, reported continued losses for the quarter and six months ended June 30, 2026 while progressing a planned sale to Eli Lilly. Six‑month total revenue was $2.7 million, mainly from Nualtis license and R&D services, against research and development expenses of $45.5 million and general and administrative expenses of $32.2 million, leading to a net loss of $62.4 million attributable to the company.
At June 30, 2026, AtaiBeckley held cash and cash equivalents of $168.8 million plus $23.0 million of short‑term U.S. Treasury securities, and management states this liquidity should fund operations for at least 12 months from issuance. The balance sheet also includes $33.96 million in COMPASS Pathways shares and $5.86 million in digital assets, alongside $57.2 million of pre‑funded warrant liabilities.
On July 15, 2026, AtaiBeckley agreed to be acquired by Eli Lilly and Company. Each common share is to be converted into $6.75 in cash plus a non‑transferable contingent value right of up to $2.50 per share, payable upon specified development and regulatory milestones for programs BPL‑003 and VLS‑01. The transaction is expected to close in the third quarter, subject to stockholder and regulatory approvals.
AtaiBeckley Inc. reported a wider loss for the three months ended March 31, 2026 as it continues to fund clinical-stage mental health programs. Total revenue was $0.95 million, mainly from Nualtis licensing and research services, compared with $1.56 million a year earlier.
Research and development expenses rose to $17.4 million and general and administrative expenses to $14.4 million, driving a net loss attributable to stockholders of $29.8 million, or $0.08 per share, versus $26.4 million and $0.15 per share in 2025. Cash and cash equivalents were $43.1 million and short-term securities $166.8 million as of March 31, 2026, and the company states this liquidity should fund operations for at least 12 months.